Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2001

View Archived Issues

Esperion Therapeutics begins phase IIa evaluation of LUV

Versicor and Biosearch Italia strengthen BIOCOR antiinfective alliance

Synapse's p97 delivers doxorubicin across BBB in preclinical study

Xcytrin clinical development program update

Microcide and J&J companies sign new and amend existing research agreement

Topical drug delivery technologies licensed by SkyePharma

Vertex updates progress during past year, provides outlook for this year

Corixa's RC-529 adjuvant enters phase III for HBV

Pharmacological characterization of S-18616, a highly potent and selective alpha2-AR agonist

Innogenetics' HCV therapeutic successfully completes phase I and moves towards phase II

LIPID substudy confirms beneficial effects of pravastatin in patients with unstable angina

Viventia Biotech's melanoma vaccine is safe and immunogenic

Anti-vWF MAb prevents thrombus deposition and neointima formation in guinea pigs

Protein Design Labs begins phase I/II trial with SMART antibody for Crohn's disease

Aurora Biosciences and GSK enter ion channel agreement

European marketing approval announced for noninvasive lung cancer diagnostic

Watson's Aslera scheduled for March FDA Arthritis Advisory Committee review

Proteomics-based RA diagnostics alliance formed by Roche and Millennium

UCB's nonsedating antihistamine approved in Germany

Authorization for pivotal trials of Generx sought in U.S.

Aixlie licenses cancer- and immune-related technologies from Ohio State

Successful phase I results for Enzo Biochem's HIV-1 gene medicine HGTV-43

Knoll patents compounds useful for depression and other disorders

Benzenesulfonamide-based inhibitors of ATP-sensitive K+ channels

DPP IV inhibitors synthesized at MCRF and their use

Sankyo's new HIV protease inhibitors show nanomolar activity

Japanese lab presents new series of TNF-alpha production inhibitors

Natural compounds for obesity with affinity for NPY receptors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 31, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026